19. (Amended) A method of treating an inflammatory disorder in a subject, said method comprising:

B1

administering, to the subject, a gene delivery vehicle for use in the subject, said gene delivery vehicle comprising:

a gene capable of expressing an apoptosis inducing agent exhibiting its effect in aberrant cells involved with or related to immune diseases.

20. A method of treating an immune disease in a subject, said method comprising:

administering, to the subject, a gene delivery vehicle comprising a gene capable of expressing an apoptosis inducing agent that exhibits effects in aberrant cells involved with or related to immune diseases.

21. The method according to claim 19, wherein said gene delivery vehicle further comprises a suicide gene.

22. The method according to claim 21, wherein said suicide gene is inducible.

23. The method according to claim 19, wherein said gene delivery vehicle has a tropism for hematopoietic cells.

24. The method according to claim 19, wherein said gene delivery vehicle has a tropism for fibroblast-like synoviocytes.

25. The method according to claim 19, wherein said gene delivery vehicle has been provided with a targeting means.

B2

26. (Amended) The method according to claim 19, wherein said gene delivery vehicle comprises a recombinant adenovirus.

31. The method according to claim 25, wherein said gene delivery vehicle has been provided with a targeting means for fibroblast-like synoviocytes.

33. The method according to claim 21, wherein said gene delivery vehicle has a tropism for hematopoietic cells.

34. The method according to claim 21, wherein said gene delivery vehicle has a tropism for fibroblast-like synoviocytes.

35. The method according to claim 21, wherein said gene delivery vehicle has been provided with a targeting means.

B3 36. (Amended) The method according to claim 21, wherein said gene delivery vehicle comprises a recombinant adenovirus.